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***Dear Editor,***

Recently, Punzi and colleagues published a study about the role of WDR5 in breast cancer metastasis (Punzi et al., 2019\[[@R17]\]). WDR5 is involved in epigenetic regulation complexes and has been reported to influence the expression of numerous genes, including N-cadherin, Snail1 and vimentin (Aho et al., 2019\[[@R1]\]; Ford and Dingwall, 2015\[[@R6]\]; Wu et al., 2011\[[@R25]\]; Chen et al., 2017\[[@R5]\]; Tan et al., 2017\[[@R23]\]). Several studies suggested WDR5 as a therapeutic target (Ye et al., 2019\[[@R26]\]\[[@R27]\]; Macdonald et al., 2019\[[@R14]\]; Aho et al., 2019\[[@R1]\]; Zhang et al., 2018\[[@R28]\]; Lu et al., 2018\[[@R13]\]). In their present work, Punzi and colleagues report that downregulation of WDR5 by shRNA in breast cancer cells antagonizes the epithelial-to-mesenchymal transition through re-differentiation and reduces metastasis in a mouse model (Punzi et al., 2019\[[@R17]\]). Moreover, an association of high WDR5 expression with shorter metastasis-free survival was observed in a cohort of breast cancer patients (Punzi et al., 2019\[[@R17]\]). A further important finding of this study is that WDR5 activates TGFβ in breast cancer and that targeting the WDR5-TGFβ axis by a small molecular inhibitor reduces the migratory potential of breast cancer cells. Metastasis of breast cancer is a complex process (Loi et al., 2019\[[@R12]\]; von Minckwitz et al., 2019\[[@R24]\]; Gogiashvili, 2018\[[@R8]\]; Stoeber, 2017\[[@R22]\]). Besides epithelial-to-mesenchymal transition, genes involved in proliferation (Schmidt et al., 2018\[[@R19]\]), immune cell infiltration (Schmidt et al., 2012\[[@R18]\], 2018\[[@R19]\]; Heimes et al., 2017\[[@R9]\]\[[@R10]\]; Godoy et al., 2014\[[@R7]\]), oxidative stress response (Cadenas et al., 2010\[[@R2]\], 2014\[[@R3]\], 2019\[[@R4]\]; Hellwig et al., 2016\[[@R11]\]) and inflammatory factors (Mattsson et al., 2015\[[@R16]\]; Sicking et al., 2014\[[@R20]\]) are of relevance; also key enzymes of phosphocholine metabolism have been shown to control breast and ovarian cancer metastasis (Marchan et al., 2017\[[@R15]\]; Stewart et al., 2012\[[@R21]\]). It will be interesting to learn in the next years, whether WDR5 targeting compounds can be identified that have a perspective to be tested in clinical studies.
